4.8 Article

Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts

Journal

BIOMATERIALS
Volume 220, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2019.119402

Keywords

Osteomimicry; Prostate cancer; Cancer model; Bone metastasis; Patient-derived xenograft; Osteocyte

Funding

  1. Advance Queensland (AQ) Maternity Fund Award from the Queensland Government (DSITI)
  2. National Health and Medical Research Council (NHMRC) Peter Doherty Early Career Research Fellowship (RF) [APP1091734]
  3. John Mills Young Investigator Award from the Prostate Cancer Foundation of Australia (PCFA) [YI0715]
  4. JJ Richards & Sons via an In Vitro Excellence Research grant
  5. QUT
  6. AQ RF (QLD)
  7. NHMRC PRF
  8. Humboldt RF
  9. ARC Industrial Transformation Training Centre in Additive Biomanufacturing [IC160100026]
  10. World Cancer Foundation
  11. Movember Revolutionary Team Award (Movember)
  12. Australian Government
  13. NHMRC
  14. National Breast Cancer Foundation
  15. PCFA
  16. Movember Revolutionary Team Award (PCFA)

Ask authors/readers for more resources

Representative in vitro models that mimic the native bone tumor microenvironment are warranted to support the development of more successful treatments for bone metastases. Here, we have developed a primary cell 3D model consisting of a human osteoblast-derived tissue-engineered construct (hOTEC) indirectly co-cultured with patient-derived prostate cancer xenografts (PDXs), in order to study molecular interactions in a patient-derived microenvironment context. The engineered biomimetic microenvironment had high mineralization and embedded osteocytes, and supported a high degree of cancer cell osteomimicry at the gene, protein and mineralization levels when co-cultured with prostate cancer PDXs from a lymph node metastasis (LuCaP35) and bone metastasis (BM18) from patients with primary prostate cancer. This fully patient-derived model is a promising tool for the assessment of new molecular mechanisms and as a personalized pre-clinical platform for therapy testing for patients with prostate cancer bone metastases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available